news agency

Phase II of the trial in patients of Hipra’s Spanish vaccine against Covid-19 authorized

The Spanish Agency for Medicines and Health Products has authorized this Monday the transition to phase II of the clinical trial of the Covid vaccine being developed by Hipra laboratories, in which 1,000 volunteers from ten hospitals will participate.

This was announced by the President of the Government, Pedro Sánchez, during the presentation of the Strategic Projects for Economic Recovery and Transformation, in which he recalled that this phase will count with an investment of almost 15 million euros.

“It is one more reason to feel pride in the country,” celebrated the Chief Executive, who has described the authorization of the Aemps as “fantastic news for science”.

The Spanish company HIPRA plans to produce 400 million doses of its Covid-19 vaccine during 2022. It is a recombinant protein vaccine that has been designed to optimize its safety and induce a powerful immune response that neutralizes the virus.

Sánchez has been accompanied by the Minister of Finance and Public Function, María Jesús Montero, the Minister of Industry, Commerce and Tourism, Reyes Maroto, the Minister of Health, Carolina Darias, and the Minister of Science and Innovation, Diana Morant.

You may also like

Hot News

TRENDING NEWS

Subscribe

follow us

Immediate Access Pro